11/14/2024 | Press release | Distributed by Public on 11/14/2024 06:06

Nuvectis Pharma Reports Encouraging NXP800 Interim Data Supporting Ongoing Enrollment in Phase 1b Study in Patients with Platinum Resistant ARID1a Mutated Ovarian Cancer

Please select the service you want to use:

• Newsvine
• Digg
• Delicious
• StumbleUpon
• Technorati
• Buzz
• Favorites
• Google Reader

 Back

 Download the original document